Major R&D Pipeline
As of November 8, 2024
(Updated based on quarterly financial disclosure)
-
●：Development progress from July 2024 onwards ○：Development progress from April 2024 onwards
Neurology
Dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Leqembi」(lecanemab/BAN2401) Treatment for Alzheimer’s disease (AD)/ anti-Aβ protofibril antibody In-license (BioArctic AB) Injection (intravenous infusion, subcutaneous injection) Joint development with Biogen Inc. | ||||
| Early AD | 301 (Clarity AD) | Asia (South Korea) | ○ | Approval (April 2024) |
| Great Britain | ● | Approval (August 2024) | ||
| Europe | Submission
(accepted: January 2023) |
|||
| IV maintenance dosing for early AD (Additional Dosage and Administration) | 201／301 | US | ○ | Submission (June 2024) |
| Maintenance dosing of a subcutaneous injection formulation for early AD (Additional Formulation) | 301 | US | ● | Completion of Rolling Submission (October 2024) |
| Preclinical AD | 303 (AHEAD 3-45) | Japan/US/Europe | PⅢ | |
| E2814 anti-MTBR tau antibody Collaboration (University College London) Injection | ||||
| Dominantly inherited AD (in combination with lecanemab) | Tau Nexgen | JP/US/EU | PⅡ/Ⅲ | |
| Dominantly inherited AD | 103 | US/EU | PⅠb/Ⅱ | |
| Sporadic early AD (in combination with lecanemab) | 202 | JP/US | ● | PⅡ |
| E2511 TrkA integrated synapse regenerant In-house Oral | ||||
| AD | - | US | PⅠ | |
| E2025 Anti-EphA4 antibody In-house Injection | ||||
| AD | - | US | PⅠ | |
Neurological diseases other than dementia
*You can scroll to the left or right here
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Fycompa」(perampanel/E2007) Antiepileptic agent / AMPA receptor antagonist In-house Oral / Injection | ||||
| Adjunctive therapy for primary generalized tonic-clonic seizures (Additional Indication) | 332 | China | ○ | Approval (April 2024) |
| 「Dayvigo」(lemborexant/E2006) Insomnia treatment / Orexin receptor antagonist In-house Oral | ||||
| Insomnia disorder | 311 | China | Submission (accepted: January 2024) | |
| 「Rozebalamin」(mecobalamin/E0302) Treatment for Amyotrophic lateral sclerosis (ALS) In-house Injection | ||||
| ALS | JETALS (IIS) | Japan | ● | Approval (September 2024) |
| lorcaserin/E2023 Treatment for Dravet syndrome / serotonin 2C receptor agonist In-license (Arena Pharmaceuticals) Oral | ||||
| Dravet syndrome | 304 | US | PⅢ | |
| E2086 Orexin receptor agonist In-house Oral | ||||
| Narcolepsy | - | US | PⅠb | |
| EA4017 In-house Oral | ||||
| Chemotherapy-induced peripheral neuropathy (Development conducted by EA Pharma) | - | Japan | PⅠ | |
Oncology
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「Lenvima/Kisplyx」(lenvatinib/E7080) Anticancer agent / kinase inhibitor In-house Oral | ||||
| In combination with anti-PD-1 therapy pembrolizumab, joint development with Merck & Co., Inc., Rahway, NJ, USA, through an affiliate (Additional Indication) | ||||
| Hepatocellular carcinoma (in combination with transcatheter arterial chemoembolization) / First-line | LEAP-012 | JP/US/EU/CH | PⅢ | |
| Esophageal carcinoma (in combination with chemotherapy) / First-line | LEAP-014 | JP/US/EU/CH | PⅢ | |
| Gastric cancer (in combination with chemotherapy) / First-line | LEAP-015 | JP/US/EU/CH | PⅢ | |
| In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Indication) | ||||
| Hepatocellular carcinoma | - | Japan | PⅠb | |
| 「Halaven」(eribulin/E7389) Anticancer agent / microtubule dynamics inhibitor In-house Injection | ||||
| Monotherapy (Additional Formulation) | ||||
| Liposomal formulation | - | JP/EU | PⅠ | |
| In combination with anti-PD-1 antibody nivolumab, joint development with Ono Pharmaceutical (Additional Formulation) | ||||
| Liposomal formulation | 120 | Japan | PⅠb/Ⅱ | |
| 「Tasfygo」(tasurgratinib/E7090) Anticancer agent / FGFR1, FGFR2, FGFR3 inhibitor In-house Oral | ||||
| Biliary tract cancer with FGFR2 gene fusion | 201 | Japan | ● | Approval (September 2024) |
| Breast cancer | - | Japan | PⅠb | |
| farletuzumab ecteribulin（FZEC）/MORAb-202 Anticancer agent / Folate receptor α targeted antibody drug conjugate In-house Injection | ||||
| Non-small cell lung cancer | 203 | US/EU | PⅡ | |
| Ovarian cancer, peritoneal cancer, fallopian tube cancer | 205 | JP/US/EU | PⅡ | |
| Solid tumors | 201 | US/EU | PⅠ/Ⅱ | |
| BB-1701 Anticancer agent / HER2 targeted antibody drug conjugate In-house Injection | ||||
| Breast cancer | 205 | JP/US | PⅡ | |
| E7386 Anticancer agent / CBP/β-catenin interaction inhibitor Collaboration (PRISM BioLab) Oral | ||||
| Solid tumors (in combination with pembrolizumab) | 201 | JP/US/EU | PⅠb/Ⅱ | |
| Solid tumors | - | JP/US/EU | PⅠ | |
| Solid tumors (in combination with lenvatinib) | - | JP/US/EU | PⅠb | |
| H3B-6545 Anticancer agent / ERα inhibitor In-house Oral | ||||
| Breast cancer (in combination with CDK4/6 inhibitor palbociclib) | - | US/EU | PⅠb | |
| E7130 Anticancer agent Collaboration (Harvard University) Injection | ||||
| Solid tumors | - | Japan | PⅠ | |
| E7766 Anticancer agent In-house Injection | ||||
| Solid tumors | - | US/EU | PⅠb | |
Global Health
※左右にスクロールできます
| Disease | Sponsor of study | Region | Development Stage | |
|---|---|---|---|---|
| fosravuconazole/E1224 Antifungal agent / ergosterol synthesis inhibitor In-house Oral | ||||
| Eumycetoma
*Supported by GHIT fund *Eisai is mainly responsible for non-clinical studies and the provision of the investigational drug. |
DNDi・Mycetoma Research Center of the University of Khartoum | Sudan | PⅡb/Ⅲ | |
| SJ733 Antimalarial agent / ATP4 inhibitor Co-development (University of Kentucky) Oral | ||||
| Malaria
*Supported by GHIT fund *Eisai is responsible for the provision of drug substance and formulation manufacturing |
University of Kentucky | Peru | PⅡ | |
| AWZ1066S Antifilarial agent / antiwolbachia mechanism Co-development (Liverpool School of Tropical Medicine) Oral | ||||
| Lymphatic filariasis and onchocerciasis (river blindness)
*Supported by the GHIT Fund and Medical Research Council in the UK *Eisai is responsible for the provision of drug substance and formulation manufacturing |
Liverpool School of Tropical Medicine | UK | PⅠ | |
Gastrointestinal Disorders
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| MOVICOL/(AJG555) Chronic constipation treatment / polyethylene glycol preparation In-license (Norgine) Oral | ||||
| Chronic constipation in children under 2 years of age (Additional Dosage and Administration) (Development conducted by EA Pharma) | CT3 | Japan | PⅢ | |
| AJM347 In-house Oral | ||||
| Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) | - | EU | PⅠ | |
| EA1080 In-house Oral | ||||
| Inflammatory bowel disease (Joint development conducted by EA Pharma with Ensho Therapeutics, Inc) | - | EU | PⅠ | |
| EA3571 In-house Oral | ||||
| Metabolic dysfunction-associated steatohepatitis (Development conducted by EA Pharma) | - | Japan | PⅠ | |
Other
※左右にスクロールできます
| Disease | Study | Region | Development Stage | |
|---|---|---|---|---|
| 「URECE」(dotinurad / FYU-981) Treatment for Hyperuricemia and Gout / selective URAT1 inhibitor In-license (FUJI YAKUHIN) Oral | ||||
| Gout, hyperuricemia | - | Asia (Thailand) |
● |
Approval (September 2024) |
| Gout | 301 | China | Submission (accepted: January 2024) | |
| E6742 Treatment for Systemic lupus erythematosus / TLR 7/8 inhibitor In-house Oral | ||||
| Systemic lupus erythematosus | 101 | Japan | PⅠ/Ⅱ | |
| E8001 In house Injection | ||||
| Rejection reaction associated with organ transplantation | - | Japan | PⅠ | |